Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of over 15 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2018a 2019e 2020e 2021e  2022e  2023e  2024e
Core Products              
Cimzia 1,446 1,573 1,618 1,650 1,657 1,615 1,520
Vimpat 1,099 1,259 1,367 1,462 1,288 848 659
Keppra  790 747 718 666 618 579 543
Briviact 142 226 300 374 440 501 551
Neupro 321 323 327 298 253 226 206
6 Potential new Product Launches*
(global sales, non-risk adj.)
             
Evenity (romosozumab) 70   169  281  387 486  553
Midazolam nasal spray 10 27  49  69  88  102
Bimekizumab 65  189  346   505
Rozanolixizumab (Rozimab/Roza)  45 134  242 
Padsevonil 31  85   147
Anti-Tau  0  0  0  50 125

  *in the next 5 years

UCB FY Consensus Earnings Estimates (Average)

In € million 2018a 2019e 2020e 2021e 
Net Sales  4,412 4,550 4,821  5,017
Revenue  4,632 4,744 5,006 5,202
Recurring EBIT 1,105  1,051 1,127 1,281
Recurring EBITDA 1,398  1,327 1,412 1,573
Net Profit*  800 780 827 958
Core EPS (€) 4.78  4.63 4.94 5.66

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2018a 2019e 2020e 2021e  2022e  2023e  2024e
Core Products              
Cimzia 1,446 1,581 1,628 1,663 1,669 1,654 1,623
Vimpat 1,099 1,259 1,369 1,467 1,250 843 714
Keppra 790 748 713 667 623 587 551
Briviact 142 223 301 378 450 510 558
Neupro 321 327 326 289 231 185 161
6 Potential new Product Launches*
(global sales, non-risk adj.)
             
Evenity (romosozumab)  57 176  286  389  528 618 
Midazolam nasal spray 10  25  48  68   82 98
Bimekizumab  0 51  191  327  511 
Rozanolixizumab (Rozimab/Roza)  0 37  109  178
Padsevonil 10   75  151
Anti-Tau  0  0 50  125 

 *in the next 5 years

UCB FY Consensus Earnings Estimates (Median)

In € million 2018a 2019e 2020e 2021e 
Net Sales  4,412 4,538 4,825  5,033 
Revenue  4,632 4,734 5,002 5,206
Recurring EBIT 1,105  1,044 1,133 1,285
Recurring EBITDA  1,398 1,332 1,426 1,573
Net Profit*  800  756 823 960
Core EPS (€)  4.78 4.60 4.94 5.68

*attributable to UCB shareholders

Downloads:
UCB FY 2019 Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 07 November, 2019



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.